Clinical disease course and survival outcomes following disease recurrence in adenoid cystic carcinoma with and without NOTCH signaling pathway activation.
Loading...
Embargo End Date
ICR Authors
Authors
Feeney, L
Hapuarachi, B
Adderley, H
Rack, S
Morgan, D
Walker, R
Rauch, R
Herz, E
Kaye, J
Harrington, K
Metcalf, R
Hapuarachi, B
Adderley, H
Rack, S
Morgan, D
Walker, R
Rauch, R
Herz, E
Kaye, J
Harrington, K
Metcalf, R
Document Type
Journal Article
Date
2022-10-01
Date Accepted
2022-07-15
Abstract
BACKGROUND: Adenoid cystic carcinoma (ACC) is a rare salivary cancer. The highest rates of disease recurrence are in patients with NOTCH pathway activation, reported in up to 20%. Novel drugs targeting NOTCH signaling are under investigation in the recurrent/metastatic (R/M) setting. To understand their clinical utility, there is an urgent need to better characterize the disease course and outcomes following current standard of care treatment. METHODS: 120 patients with R/M ACC underwent clinical review at a single UK Cancer Centre. Patients were retrospectively assessed for tumor NOTCH pathway activation using next generation sequencing (NGS) targeting NOTCH1/2/3 genes and/or NOTCH1 intra-cellular domain (NICD1) immunohistochemistry. Demographic and treatment data were extracted from the clinical notes. Kaplan-Meier survival analysis was performed using log rank test. RESULTS: NOTCH pathway activation was identified in 13/120 patients (11 %). In 12/101 patients analyzed by NGS, NOTCH1/3 activating somatic mutations were identified, and a further patient was identified with NICD1 diffuse nuclear staining in whom NGS testing was not possible. Patients with NOTCH pathway activation had shorter median RFS (1.1 vs 3.4 years, p = 0.2032) and significantly reduced median OS from diagnosis (4.0 vs 16.3 years, p < 0.0001). There was significantly reduced median OS from time of disease recurrence/metastasis (1.9 vs 9.6 years, p < 0.0001). CONCLUSION: This study clearly demonstrates a reduction in OS from time of first confirmed disease recurrence/metastasis for patients with NOTCH pathway activated ACC. This provides support for developing new drugs for this sub-group of patients, for whom clinical outcomes are significantly worse and effective treatments are lacking.
Citation
Oral Oncology, 2022, 133 pp. 106028 -
Source Title
Oral Oncology
Publisher
ELSEVIER
ISSN
1368-8375
eISSN
1879-0593
1879-0593
1879-0593
Collections
Research Team
Targeted Therapy